Targeting FGFR signaling downstream at FRS2α may suppress FGFR-dependent tumor cells and limit CAF-mediated pro-tumor support while sparing a subset of CAFs, providing experimental support for CAF-aware strategies to target the FGFR pathway [118]. This evidence concerns the gene FRS2 and neoplasm.